

Company Profile

Medios AG is the leading provider of Specialty Pharma solutions in Germany. As a competence partner and expert, Medios covers all relevant aspects of the supply chain in this field: from pharmaceutical supply and the manufacture of patient-specific therapies to drug safety, including blistering. The focus is on six indication areas: oncology, neurology, autoimmunology, ophthalmology, infectiology and hemophilia. The aim of Medios is to ensure the best comprehensive care for patients through partnership-based collaboration and exchange between the various market participants, thus contributing to a sustainable and transparent supply of medicines.

Executive Board



Matthias Gärtner,
CEO & CFO
IT Specialist




Mi-Young Miehler,
COO
Business Economist




Christoph Prüßit,
CINO
Pharmacist

Structure and Segments



Consolidated Revenue in €m



Consolidated EBT in €m



CAGR = Compound Annual Growth Rate; *pro forma; ** adjusted for extraordinary expenses

Key Figures

| in €m | 2019 (IFRS) | 2018 (IFRS) | Change |
|--------------|----------------|----------------|---------|
| Sales | 516.8 | 327.8 | +58% |
| EBITDA adj.* | 17.7 | 11.7 | +51 |
| Margin in % | 3.4 | 3.6 | -0.2 PP |
| EBT adj.* | 16.2 | 11.0 | +48% |
| Margin in % | 3.1 | 3.3 | -0.2 PP |
| Net profit | 9.8 | 4.3 | >100% |

*adjusted for extraordinary expenses

Basic Information


as of February 2021

| | |
|----------------|---|
| Share Capital | €20,264,991 |
| No. of shares | 20,264,991* |
| Share class | No-par value bearer shares |
| WKN/ISIN | A1MMCC/DE000A1MMCC8 |
| Trading places | Regulated Market Frankfurt (Prime Standard) |
| | Member of the SDAX index |

*incl. New Shares from capital increases on 06/04/20, 04/06/20, and 21/01/21


Shareholder Structure

as of February 2021



All figures according to voting rights notifications of the notifying parties

Share Price in €



22/11/16 (IPO)

21/01/21

Investment Highlights

- Market:** Highly attractive and strongly growing Specialty Pharma market driven by structural tailwinds
- Positioning:** Uniquely positioned as first mover with clearly defined competitive advantages within the field of individualized medicine
- Business model:** Strong, synergistic business model with clear value-add for stakeholders
- Financials:** Proven financial track record with continuous, profitable asset-light growth
- Strategy:** Highly experienced management team with clear strategy for profitable growth